Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summaryMarketScreener Strategies
OFFRE
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The close medium term support offers good timing for purchasing the stock.
  • Its core activity has a significant growth potential and sales are expected to surge, according to Thomson Reuters' forecast. Indeed, those may increase by 47% by 2020.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
CELGENE CORPORATION-15.94%61 699
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092
AMGEN17.94%132 756
ABBOTT LABORATORIES20.99%121 136
ELI LILLY AND COMPANY25.89%114 197
SANOFI3.69%109 540
BRISTOL-MYERS SQUIBB COMPAN..1.58%101 584
GLAXOSMITHKLINE15.80%99 260
ASTRAZENECA10.72%92 763
NOVO NORDISK A/S-9.87%89 924
BAYER-25.23%83 828
ALLERGAN PLC16.95%64 939
More Results
Financials ($)
Sales 2018 15 133 M
EBIT 2018 8 428 M
Net income 2018 4 591 M
Debt 2018 13 270 M
Yield 2018 -
P/E ratio 2018 14,05
P/E ratio 2019 10,48
EV / Sales 2018 4,95x
EV / Sales 2019 4,07x
Capitalization 61 699 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | MarketScreener
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | MarketScreener